Match Document Document Title
9035030 Human antibodies that bind the P40 subunit of human IL-12 and methods for using the same  
Human antibodies, preferably recombinant human antibodies, that specifically bind to human interleukin-12 (hIL-12) are disclosed. Preferred antibodies have high affinity for hIL-12 and neutralize...
9028816 Polypeptides and polypeptide constructs comprising single domain antibodies directed against von Willebrand factor  
The present invention relates to polypeptides and polypeptide constructs comprising at least one single domain antibody directed against vWF, vWF A1 domain, A1 domain of activated vWF, vWF A3...
9029508 Dual variable domain immunoglobulins and uses thereof  
The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.
9023355 Compositions and methods for treating renal disease  
Compositions and methods are disclosed herein for treating or reducing the symptoms of a renal disease, such as focal segmental glomerulosclerosis (FSGS), hypertensive end-stage kidney disease...
9023358 Antibodies that bind to IL-23  
The present invention provides an antibody that binds to the p19 subunit of human IL-23 and is characterized as having high affinity, selective, and neutralizing properties. The antibody is useful...
9018357 Anti-VEGF antibodies  
Anti-VEGF antibodies and variants thereof, including those having high affinity for binding to VEGF, are disclosed. Also provided are methods of using phage display technology with naïve libraries...
9017680 Methods of administering anti-TNFα antibodies  
Methods of treating disorders in which TNFα activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind...
9017687 Low acidic species compositions and methods for producing and using the same using displacement chromatography  
The present invention relates to low acidic species (AR) compositions comprising a protein, e.g., an antibody, or antigen-binding portion thereof, and methods for producing such low AR...
9011860 Compositions for inhibiting MASP-2 dependent complement activation  
The present invention relates to anti-MASP-2 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-2 dependent complement activation.
9011861 Therapeutic compositions for the treatment of dry eye disease  
Described herein are materials and methods for treating dry eye disease in a subject.
9011858 Variable region sequences of IL-31 monoclonal antibodies and methods of use  
Novel compositions derived from antigen-binding sites of immunoglobulins having affinity for IL-31 are provided. The compositions exhibit immunological binding properties of antibody molecules...
9005620 Compounds  
Binding members, e.g. human antibody molecules, which bind interleukin-6 (IL-6) and neutralize its biological effects. Use of binding members for IL-6 in medical treatment e.g. for treating...
9005617 Antikine antibodies that bind to multiple CC chemokines  
An antikine antibody binds to two, three, four, five or more CC chemokines, such as RANTES/CCL5, MIP-1α/CCL3, MIP-1β/CCL4, or MCP-1/CCL2. Methods for affinity maturation and humanization of...
8999337 Methods for treating juvenile idiopathic arthritis by inhibition of TNFα  
The invention provides methods and compositions for the treatment of juvenile idiopathic arthritis (JIA) where a TNFα inhibitor, such as a human TNFα antibody, or antigen-binding portion thereof,...
8999330 Antagonists of IL-6 to prevent or treat thrombosis  
The present invention is directed to therapeutic methods using IL-6 antagonists such as antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat thrombosis in...
8999340 Methods for treating multiorgan, systemic degos' disease with a complement inhibitor  
The present disclosure relates to, inter alia, compositions containing an inhibitor of human complement and/or an inhibitor of interferon alpha, and the use of the compositions in methods for...
8999936 Antibodies specific for soluble amyloid beta peptide protofibrils and uses thereof  
The invention relates to an isolated monoclonal antibody or antigen-binding fragment thereof that (a) binds (i) wild-type Aβ 42/40 protofibril comprising N-terminal truncated Aβ forms and (ii) Aβ...
8992930 Extracellular IFI16 as therapeutic agents  
The present invention relates to the inhibition of the circulating extracellular form of the interferon inducible protein 16 (extracellular IFI16) for the treatment of diseases, particularly...
8992925 RANKL antibody-PTH/PTHrP chimeric molecules  
Chimeric molecules comprising receptor activator of NF-κB ligand (RANKL) antibodies and parathyroid hormone/parathyroid hormone-related protein (PTH/PTHrP) peptides are described. Compositions and...
8992913 Antagonist antibodies against GDF-8 and uses therefor  
The disclosure provides improved neutralizing anti-GDF-8 antibodies capable of substantially higher levels of expression in host cells compared to previous anti-GDF-8 antibodies. Also provided are...
8992911 Antibodies specific for sclerostin and methods for increasing bone mineralization  
Compositions and methods relating to antibodies that specifically bind to TGF-beta binding proteins are provided. These methods and compositions relate to altering bone mineral density by...
8992908 Anti-IL-6 antibodies for the treatment of oral mucositis  
The present invention is directed to therapeutic methods using IL-6 antagonists such as anti-IL-6 antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat mucositis...
8992926 Methods of administering anti-TNFα antibodies  
Methods of treating disorders in which TNFα activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind...
8992904 ***WITHDRAWN PATENT AS PER THE LATEST USPTO WITHDRAWN LIST***
Anti-IL-6 antibodies or fragments thereof to treat or inhibit cachexia, associated with chemotherapy toxicity
 
The present invention is directed to therapeutic methods and compositions, especially subcutaneous and intravenous composition using antibodies and fragments thereof having binding specificity for...
8992920 Anti-IL-6 antibodies for the treatment of arthritis  
The present invention is directed to therapeutic methods using IL-6 antagonists such as anti-IL-6 antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat...
8992922 Antagonists of IL-17A, IL-17F, and IL-23P19  
The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A, IL-17F, and IL-23. Antagonists include antibodies and antibody fragments that...
8986696 Trans-capsular administration of p38 map kinase inhibitors into orthopedic joints  
The present invention relates to trans-capsularly administering into a diseased joint an inhibitor of p38 MAP kinase or a different therapeutic agent.
8986685 Compositions and methods for increasing bone mineralization  
Described herein are pharmaceutical compositions comprising an anti-sclerostin antibody and an inhibitor of bone resorption.
8986692 Anti-VEGF monoclonal antibody and pharmaceutical composition comprising said antibody  
The present invention provides an anti-VEGF monoclonal antibody, which has the variable region of heavy chain comprising the amino acid sequences of SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:3,...
8987420 High affinity human antibodies to human angiopoietin-2  
The present invention provides antibodies that bind to angiopoietin-2 (Ang-2) and methods of using same. According to certain embodiments of the invention, the antibodies are fully human...
8986693 Use of TNFα inhibitor for treatment of psoriasis  
The invention describes methods of treating erosive polyarthritis comprising administering a TNFα antibody, or antigen-binding portion thereof. The invention also describes a method for testing...
8987418 Dual specific binding proteins directed against IL-1β and/or IL-17  
Engineered multivalent and multispecific binding proteins that bind IL-1β and/or IL-17 are provided, along with methods of making and uses in the prevention, diagnosis, and/or treatment of disease.
8980257 Antibody being capable of binding to transforming growth factor alpha and having growth-suppressing activity on cancers having Ras gene mutation  
It has been found out that among antibodies showing reactivity with wild type TGF-α, antibodies less reactive with G79A-substituted TGF-α have an excellent growth-suppressing effect on cancer...
8980261 Treatment of angiogenesis disorders  
This invention concerns pathological angiogenesis and cancer, related treatment methods, and related compositions. Also disclosed are related diagnosis kits and methods.
8980268 Methods for treating cancer by administering an anti-Ang-2 antibody  
The present invention provides antibodies that bind to angiopoietin-2 (Ang-2) and methods of using same. According to certain embodiments of the invention, the antibodies are fully human...
8974790 Methods of administering anti-TNFα antibodies  
Methods of treating disorders in which TNFα activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind...
8969040 Pharmaceutical agent comprising anti-BMP9 antibody as active ingredient for treatment of anemia such as renal anemia and cancer anemia  
The present invention provides an anti-BMP9 (Bone morphogenetic protein-9) monoclonal antibody or an antibody fragment thereof binding to human BMP9, a hybridoma producing the antibody or the...
8968731 Treatment of uveitis  
The present invention relates generally to the use of antagonists of G-CSF, and/or its receptor (G-CSFR) in the treatment of uveitis. The present invention contemplates, therefore, the inhibition...
8969322 Extracorporeal devices and methods of treating complications of pregnancy  
The invention features extracorporeal methods for the treatment of a subject having a pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia. The invention also features...
8969291 Methods for decreasing leptin levels or activity for treating inflammation  
The present invention is directed to methods for modulating the Th1 /Th2 cell balance toward anti-inflammatory cytokine producing cells in a subject comprising decreasing the amount, the...
8962249 Methods for detecting and treating systemic lupus erythematous  
The invention provides methods and compositions useful for detecting autoimmune disorders.
8961974 Multiple-variable dose regimen for treating TNFα-related disorders  
Multiple-variable dose methods for treating TNFα-related disorders, including Crohn's disease and psoriasis, comprising administering TNFα inhibitors, including TNFα antibodies, are described....
8961973 Multiple-variable dose regimen for treating TNFα-related disorders  
Multiple-variable dose methods for treating TNFα-related disorders, including Crohn's disease and psoriasis, comprising administering TNFα inhibitors, including TNFα antibodies, are described....
8956607 Humanized anti-IL 10 antibodies for the treatment of systemic lupus erythematosus (SLE)  
Provided is a humanized or chimeric antibody or fragment thereof capable of binding to interleukin-10 (IL-10), wherein said antibody or fragment thereof: (i) binds to the same region of IL-10 as...
8951522 Methods for treating conditions associated with MASP-2 dependent complement activation  
In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject...
8945546 IP-10 antibodies and their uses  
The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to IP-10 with high affinity, inhibit the binding of IP-10 to its receptor, inhibit...
8945553 Bispecific antibodies to IL-23 and IL-17A/F  
The present invention relates to antagonizing the activity of IL-17A, IL-17F and IL-23 using bispecific antibodies that comprise a binding entity that is cross-reactive for IL-17A and IL-17F and a...
8945562 Anti-complement C1s antibodies  
The present disclosure provides antibodies that bind complement C1s protein; and nucleic acid molecules that encode such antibodies. The present disclosure also provides compositions comprising...
8940883 Anti-fXI antibodies and methods of use  
Disclosed herein are monoclonal antibodies specific for factor XI (fXI) that prevent activation of fXI by factor XIIa (fXIIa). The monoclonal antibodies are universal fXI antibodies, capable of...
8940303 CD127 binding proteins  
Antigen binding proteins which bind to human IL-7 receptor (CD127) are provided. The antigen binding proteins are typically antibodies, and are useful in the treatment of diseases or disorders in...